Home > Good tolerance of post-RP radiotherapy ± short term ADT

Good tolerance of post-RP radiotherapy ± short term ADT

Dr Paul Sargos (Institut Bergonié, France) presented the first results of the GETUG-AFU 22 study and won the second prize in the EAU20 Best Abstract Awards Oncology [1].

The multicentre, randomised, phase 2 GETUG-AFU 22 study, compared 6 months of degarelix short-term androgen deprivation therapy (ADT) in combination with radiotherapy and radiotherapy alone as salvage treatment for patients with detectable prostate-specific antigen (PSA) levels after radical prostatectomy (RP). The primary efficacy endpoint was event-free survival, which will be reported later this year. Key secondary endpoints were toxicity (as measured by CTCAE V4.0) and quality of life (QLQ-C30 and QLQ-PR25) results.

Dr Sargos presented the key secondary endpoints in 125 patients with localised prostate cancer, treated by RP, with a PSA level post-RP ≥0....



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on




Notice: Undefined variable: conference_obj in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 43

Warning: Creating default object from empty value in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 44

Notice: Undefined property: stdClass::$category_parent in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 45

Notice: Undefined property: stdClass::$term_id in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 53

Notice: Undefined property: stdClass::$term_id in /home/daan/projects/medicalconferences_test/wp-content/themes/writers-blogily-child/template-parts/content-widget-toc.php on line 64